THERAPEUTIC TARGETING OF NONMALIGNANT "ACCESSORY" CELLS IN BONE METASTASES OF HORMONE-RESISTANT ER-POSITIVE BREAST CANCER

$635,533FY2015Department of the ArmyDOD

Dana-Farber Cancer Institute, Inc.

Investigators